ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 102 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $384,232 | -49.6% | 72,360 | -9.6% | 0.00% | – |
| Q2 2023 | $762,686 | -53.3% | 80,030 | -46.1% | 0.00% | -100.0% |
| Q1 2023 | $1,633,500 | +186.7% | 148,500 | +285.7% | 0.00% | – |
| Q4 2022 | $569,800 | +5.3% | 38,500 | +36.0% | 0.00% | – |
| Q3 2022 | $541,000 | -10.3% | 28,300 | 0.0% | 0.00% | – |
| Q2 2022 | $603,000 | +54.2% | 28,300 | +39.4% | 0.00% | – |
| Q1 2022 | $391,000 | -7.1% | 20,300 | 0.0% | 0.00% | – |
| Q4 2021 | $421,000 | -6.2% | 20,300 | +8.0% | 0.00% | – |
| Q3 2021 | $449,000 | -12.5% | 18,800 | 0.0% | 0.00% | – |
| Q2 2021 | $513,000 | +29.5% | 18,800 | +37.2% | 0.00% | – |
| Q1 2021 | $396,000 | -10.8% | 13,700 | -13.3% | 0.00% | – |
| Q4 2020 | $444,000 | -80.0% | 15,800 | -79.1% | 0.00% | -100.0% |
| Q3 2020 | $2,217,000 | -5.2% | 75,664 | -2.2% | 0.00% | 0.0% |
| Q2 2020 | $2,339,000 | +14.0% | 77,364 | +12.4% | 0.00% | 0.0% |
| Q1 2020 | $2,051,000 | – | 68,836 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,434,232 | $162,443,000 | 13.84% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $76,641,000 | 7.44% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,960,000 | 5.19% |
| Logos Global Management LP | 1,500,000 | $28,890,000 | 3.75% |
| Omega Fund Management, LLC | 623,836 | $12,015,000 | 2.46% |
| Orbimed Advisors | 6,073,850 | $116,982,000 | 1.90% |
| MPM BioImpact LLC | 258,500 | $4,979,000 | 1.34% |
| 1492 Capital Management LLC | 75,192 | $1,448,000 | 0.77% |
| SECTORAL ASSET MANAGEMENT INC | 219,136 | $4,221,000 | 0.75% |
| EcoR1 Capital, LLC | 895,503 | $17,247,000 | 0.54% |